Do analysts prefer OKYO or QCLS?

OKYO Pharma presently has a consensus price target of $6.33, indicating a potential upside of 295.83%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe OKYO Pharma is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, OKYO or QCLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is OKYO or QCLS more profitable?

OKYO Pharma's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts prefer QCLS or MCRB?

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 152.83%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is QCLS or MCRB more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Seres Therapeutics N/A -130.29% -35.35%

Do analysts recommend CTOR or QCLS?

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 759.60%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CTOR or QCLS?

Citius Oncology is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is CTOR or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts recommend QCLS or EDSA?

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 38.42%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, QCLS or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is QCLS or EDSA more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Edesa Biotech N/A -286.52% -75.36%

Do analysts recommend INKT or QCLS?

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 192.15%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, INKT or QCLS?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is INKT or QCLS more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Mymd Pharmaceuticals N/A -76.40% -35.10%

Mymd Pharmaceuticals (QCLS) Competitors

$3.83 +0.02 (+0.52%)

As of 10:51 AM Eastern

Compare

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include OKYO Pharma (OKYO), Seres Therapeutics (MCRB), Citius Oncology (CTOR), Edesa Biotech (EDSA), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.

How does Mymd Pharmaceuticals compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

OKYO Pharma's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

OKYO Pharma has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

OKYO Pharma presently has a consensus price target of $6.33, indicating a potential upside of 295.83%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe OKYO Pharma is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, OKYO Pharma had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for OKYO Pharma and 0 mentions for Mymd Pharmaceuticals. OKYO Pharma's average media sentiment score of 0.49 beat Mymd Pharmaceuticals' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Mymd Pharmaceuticals	Neutral

Summary

OKYO Pharma beats Mymd Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Seres Therapeutics had 9 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 9 mentions for Seres Therapeutics and 0 mentions for Mymd Pharmaceuticals. Seres Therapeutics' average media sentiment score of 1.13 beat Mymd Pharmaceuticals' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
Seres Therapeutics	Positive

Seres Therapeutics has higher revenue and earnings than Mymd Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Seres Therapeutics	$790K	82.39	$5.70M	-$5.17	N/A

Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 152.83%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mymd Pharmaceuticals' return on equity of -76.40% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Seres Therapeutics	N/A	-130.29%	-35.35%

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market.

Summary

Seres Therapeutics beats Mymd Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

In the previous week, Citius Oncology's average media sentiment score of 0.00 equaled Mymd Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Citius Oncology	Neutral
Mymd Pharmaceuticals	Neutral

Citius Oncology is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Mymd Pharmaceuticals' return on equity of -76.40% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 759.60%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Citius Oncology has a beta of 3.41, meaning that its share price is 241% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Citius Oncology beats Mymd Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Edesa Biotech (NASDAQ:EDSA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 38.42%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Mymd Pharmaceuticals' return on equity of -76.40% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Edesa Biotech	N/A	-286.52%	-75.36%

Mymd Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
Edesa Biotech	Neutral

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Edesa Biotech beats Mymd Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, MiNK Therapeutics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Mymd Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 0.00 equaled Mymd Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Mymd Pharmaceuticals	Neutral

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 192.15%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Summary

MiNK Therapeutics beats Mymd Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$15.97M	$610.21M	$4.34B	$12.12B
Dividend Yield	N/A	N/A	11.45%	5.88%
P/E Ratio	-0.19	N/A	22.08	23.96
Price / Sales	N/A	150.92	154.10	107.19
Price / Cash	N/A	352.76	39.06	53.76
Price / Book	0.74	37.22	15.07	6.40
Net Income	-$11.63M	-$18.48M	$115.37M	$337.03M
7 Day Performance	-4.73%	0.22%	-1.66%	-0.86%
1 Month Performance	-8.37%	-8.38%	-2.39%	0.69%
1 Year Performance	N/A	-37.14%	11.70%	29.23%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	1.0629 of 5 stars	$3.83 +0.5%	N/A	N/A	$15.97M	N/A	N/A	6	Positive News
OKYO OKYO Pharma	2.8193 of 5 stars	$1.59 +1.3%	$6.33 +298.3%	-32.6%	$63.67M	N/A	N/A	7	News Coverage
MCRB Seres Therapeutics	2.9283 of 5 stars	$6.61 +2.3%	$22.00 +232.8%	-18.9%	$62.56M	$790K	N/A	330	Analyst Forecast Analyst Revision
CTOR Citius Oncology	1.4628 of 5 stars	$0.67 +1.4%	$6.00 +795.9%	-74.2%	$61.39M	N/A	N/A	N/A	Gap Up
EDSA Edesa Biotech	0.5958 of 5 stars	$7.35 +6.8%	$5.00 -32.0%	+297.5%	$61.18M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

How does Mymd Pharmaceuticals compare to OKYO Pharma?

Summary

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to Citius Oncology?

Summary

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

How does Mymd Pharmaceuticals compare to OKYO Pharma?

Is OKYO or QCLS more profitable?

Which has more volatility and risk, OKYO or QCLS?

Do analysts prefer OKYO or QCLS?

Do institutionals and insiders believe in OKYO or QCLS?

Which has higher earnings and valuation, OKYO or QCLS?

Does the media refer more to OKYO or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Does the media refer more to QCLS or MCRB?

Which has higher earnings & valuation, QCLS or MCRB?

Do analysts prefer QCLS or MCRB?

Is QCLS or MCRB more profitable?

Do institutionals and insiders have more ownership in QCLS or MCRB?

Which has more volatility and risk, QCLS or MCRB?

Summary

How does Mymd Pharmaceuticals compare to Citius Oncology?

Does the media favor CTOR or QCLS?

Which has stronger valuation & earnings, CTOR or QCLS?

Is CTOR or QCLS more profitable?

Do analysts recommend CTOR or QCLS?

Which has more volatility and risk, CTOR or QCLS?

Do institutionals & insiders believe in CTOR or QCLS?

Summary

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Do analysts recommend QCLS or EDSA?

Which has higher earnings & valuation, QCLS or EDSA?

Is QCLS or EDSA more profitable?

Which has more risk and volatility, QCLS or EDSA?

Does the media refer more to QCLS or EDSA?

Do insiders and institutionals hold more shares of QCLS or EDSA?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Does the media refer more to INKT or QCLS?

Do insiders and institutionals believe in INKT or QCLS?

Do analysts recommend INKT or QCLS?

Which has stronger valuation & earnings, INKT or QCLS?

Which has more risk and volatility, INKT or QCLS?

Is INKT or QCLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools